Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study
Anavex Life Sciences Corp. (AVXL)
NASDAQ:AMEX Investor Relations:
anavex.com/share-data
Company Research
Source: GlobeNewswire
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today presented preliminary clinical efficacy data from the PK cohort (Part A) of the U.S. Phase 2 Rett syndrome clinical trial ANAVEX®2-73-RS-001. “The data from the PK cohort (Part A, n=6) is very encouraging because of the (1) magnitude of change (large to very large effect sizes: Cohen’s d: RSBQ Total 1.47; Cohen’s d: Glutamate 1.11), (2) the efficacy signal on both caregiver- and clinician-based measures of severity and correlations with key biomarker related to disease pathogenesis (Glutamate), (3) the short duration of treatment with ANAVEX®2-73 (blarcamesine), (4) the relatively low dose, (5) th
Show less
Read more
Impact Snapshot
Event Time:
AVXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVXL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVXL alerts
High impacting Anavex Life Sciences Corp. news events
Weekly update
A roundup of the hottest topics
AVXL
News
- Anavex Life Sciences Corp. (NASDAQ: AVXL) had its price target raised by analysts at HC Wainwright from $40.00 to $42.00. They now have a "buy" rating on the stock.MarketBeat
- We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn [Yahoo! Finance]Yahoo! Finance
- Anavex Life Sciences Corp. (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $46.00 price target on the stock.MarketBeat
- Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business UpdateGlobeNewswire
AVXL
Earnings
- 8/6/24 - Beat
AVXL
Sec Filings
- 12/23/24 - Form 4
- 12/23/24 - Form 4
- 12/23/24 - Form 10-K
- AVXL's page on the SEC website